The Azurity partnership is a major de-risking event that provides a clear path to commercialization and removes near-term bankruptcy risk. The stock should re-rate on the validation and cash infusion. The primary catalyst is now the FDA decision on D-PLEX100 expected in Q4 2026. Traders should monitor for any FDA advisory committee meeting announcements or PDUFA date updates.
Price Chart
Executive Summary
PolyPid reported H1 2026 results showing a net loss of $15.6M (improved from $18.2M in H1 2025) with cash of $6.6M and a going-concern warning. The critical subsequent event is a July 17, 2026 license and supply agreement with Azurity for D-PLEX100 in the US and Canada, which includes a $15M upfront payment, a $15M milestone for FDA NDA acceptance (achieved in July 2026), over $290M in potential milestones, and tiered royalties. This deal provides near-term cash runway and validates the asset, but the company remains pre-revenue and faces binary FDA risk in Q4 2026.
Key Facts
- Net loss improved to $15.6M in H1 2026 from $18.2M in H1 2025.
- Cash and cash equivalents were $6.6M as of June 30, 2026.
- Auditors express substantial doubt about the company's ability to continue as a going concern.
- On July 17, 2026, PolyPid entered a License and Supply Agreement with Azurity for D-PLEX100 in the US and Canada.
- PolyPid received a $15M upfront payment and achieved a $15M milestone for FDA NDA acceptance (July 2026).
- PolyPid is eligible for over $290M in additional regulatory, development, and sales-based milestones.
- PolyPid will manufacture and supply D-PLEX100 and receive tiered royalties from mid-teen to mid-twenties percentages.
- The company anticipates a potential FDA decision on D-PLEX100 in Q4 2026 under the PDUFA timeline.
- The Kreos loan was fully repaid in May 2026.
- D-PLEX100 met primary and all key secondary endpoints in the SHIELD II Phase 3 trial with a 60% reduction in SSIs (p<0.005).
Financial Impact
The Azurity deal provides $30M in near-term cash ($15M upfront + $15M milestone), with potential for over $290M in future milestones and tiered mid-teen to mid-twenties royalties. This transforms the liquidity outlook and removes the immediate going-concern risk.
Risk Factors
- FDA may not approve D-PLEX100 in Q4 2026, leading to a binary downside event.
- The company still has no approved products or revenue, and future funding may still be needed.
- Azurity's commercialization execution is unproven for this product.
- Significant warrant overhang remains with 7.8M warrants outstanding, representing ~38% dilution on current shares.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-088439 |
| Document: ea0300231-6k_polypid.htm | 0001213900-26-088439 |
| Document: ea030023101ex99-2.htm | 0001213900-26-088439 |
| Document: 0001213900-26-088439-index-headers.html | 0001213900-26-088439 |
| Document: 0001213900-26-088439-index.html | 0001213900-26-088439 |
| Document: 0001213900-26-088439.txt | 0001213900-26-088439 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $4.90 | awaiting T+60 | — | $5.77 (+17.75%) |
Oct 1, 2026 26d ago | 6-K | $5.37 | awaiting T+60 | — | $5.77 (+7.45%) |
Oct 1, 2026 26d ago | Press Release | $5.37 | awaiting T+60 | — | $5.77 (+7.45%) |
Oct 1, 2026 26d ago | 6-K | $5.37 | awaiting T+60 | — | $5.77 (+7.45%) |
Oct 1, 2026 26d ago | Press Release | $5.37 | awaiting T+60 | — | $5.77 (+7.45%) |
Aug 12, 2026 10w ago | 6-K | $4.78 | awaiting T+60 | — | $5.77 (+20.71%) |
Aug 12, 2026 10w ago | 6-K | $4.84 | awaiting T+60 | — | $5.77 (+19.21%) |
Aug 12, 2026 10w ago | Press Release | $4.84 | awaiting T+60 | — | $5.77 (+19.21%) |
Jul 29, 2026 12w ago | 6-K | $4.08 $5.13 | ▲ +25.74% | ▲ +21.01% | $5.77 (+41.42%) |
Jul 21, 2026 14w ago | 6-K | $3.74 $4.83 | ▲ +29.14% | ▲ +26.30% | $5.77 (+54.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers